Connection

Andrew Kraft to Cell Line, Tumor

This is a "connection" page, showing publications Andrew Kraft has written about Cell Line, Tumor.
Connection Strength

1.628
  1. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
    View in: PubMed
    Score: 0.140
  2. Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. Cell Chem Biol. 2019 08 15; 26(8):1110-1121.e4.
    View in: PubMed
    Score: 0.118
  3. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther. 2018 12; 17(12):2710-2721.
    View in: PubMed
    Score: 0.112
  4. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget. 2017 May 02; 8(18):30199-30216.
    View in: PubMed
    Score: 0.102
  5. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther. 2016 07; 15(7):1637-47.
    View in: PubMed
    Score: 0.095
  6. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal. 2015 Jan; 27(1):135-46.
    View in: PubMed
    Score: 0.086
  7. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul; 34(13):2517-32.
    View in: PubMed
    Score: 0.083
  8. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013 Jun 01; 73(11):3402-11.
    View in: PubMed
    Score: 0.077
  9. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012 Jan 01; 72(1):294-303.
    View in: PubMed
    Score: 0.070
  10. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2):528-33.
    View in: PubMed
    Score: 0.066
  11. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 2011 Jan 15; 71(2):506-15.
    View in: PubMed
    Score: 0.065
  12. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 Jan 28; 115(4):824-33.
    View in: PubMed
    Score: 0.061
  13. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83.
    View in: PubMed
    Score: 0.059
  14. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 05; 283(36):25003-13.
    View in: PubMed
    Score: 0.055
  15. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther. 2008 May; 7(5):1091-100.
    View in: PubMed
    Score: 0.055
  16. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther. 2007 Jul; 6(7):1067-73.
    View in: PubMed
    Score: 0.052
  17. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51.
    View in: PubMed
    Score: 0.045
  18. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9.
    View in: PubMed
    Score: 0.044
  19. RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2005 Feb 15; 65(4):1615-6; author reply 1616-7.
    View in: PubMed
    Score: 0.044
  20. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. Mol Cancer Ther. 2020 09; 19(9):1809-1821.
    View in: PubMed
    Score: 0.032
  21. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 2020 05; 14(5):974-990.
    View in: PubMed
    Score: 0.031
  22. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res. 2019 02 01; 25(3):1036-1049.
    View in: PubMed
    Score: 0.028
  23. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res. 2018 01 01; 24(1):169-180.
    View in: PubMed
    Score: 0.026
  24. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28.
    View in: PubMed
    Score: 0.023
  25. Reducing CD73 expression by IL1?-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014 Nov 01; 74(21):6048-59.
    View in: PubMed
    Score: 0.021
  26. Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling. Proteomics Clin Appl. 2013 Jun; 7(5-6):367-71.
    View in: PubMed
    Score: 0.019
  27. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res. 2003 Dec 01; 63(23):8079-84.
    View in: PubMed
    Score: 0.010
  28. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.